241 related articles for article (PubMed ID: 2410113)
1. Implications of the discovery of HTLV-III for the treatment of AIDS.
Yarchoan R; Mitsuya H; Matsushita S; Broder S
Cancer Res; 1985 Sep; 45(9 Suppl):4685s-4688s. PubMed ID: 2410113
[TBL] [Abstract][Full Text] [Related]
2. Protection of T cells against infectivity and cytopathic effect of HTLV-III in vitro.
Mitsuya H; Matsushita S; Yarchoan R; Broder S
Princess Takamatsu Symp; 1984; 15():277-88. PubMed ID: 6085846
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of infectivity of HTLV-III in vitro.
Mitsuya H; Matsushita S; Harper ME; Broder S
Cancer Res; 1985 Sep; 45(9 Suppl):4583s-4587s. PubMed ID: 2990689
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of retroviral DNA polymerase: their implication in the treatment of AIDS.
Chandra P; Vogel A; Gerber T
Cancer Res; 1985 Sep; 45(9 Suppl):4677s-4684s. PubMed ID: 2410112
[TBL] [Abstract][Full Text] [Related]
5. A pathogenic retrovirus (HTLV-III) linked to AIDS.
Broder S; Gallo RC
N Engl J Med; 1984 Nov; 311(20):1292-7. PubMed ID: 6208484
[TBL] [Abstract][Full Text] [Related]
6. Molecular biology of human T-lymphotropic retroviruses.
Wong-Staal F; Ratner L; Shaw G; Hahn B; Harper M; Franchini G; Gallo R
Cancer Res; 1985 Sep; 45(9 Suppl):4539s-4544s. PubMed ID: 2990683
[TBL] [Abstract][Full Text] [Related]
7. Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III.
Mitsuya H; Popovic M; Yarchoan R; Matsushita S; Gallo RC; Broder S
Science; 1984 Oct; 226(4671):172-4. PubMed ID: 6091268
[TBL] [Abstract][Full Text] [Related]
8. Prospective study of cytotoxic T lymphocyte responses to influenza and antibodies to human T lymphotropic virus-III in homosexual men. Selective loss of an influenza-specific, human leukocyte antigen-restricted cytotoxic T lymphocyte response in human T lymphotropic virus-III positive individuals with symptoms of acquired immunodeficiency syndrome and in a patient with acquired immunodeficiency syndrome.
Shearer GM; Salahuddin SZ; Markham PD; Joseph LJ; Payne SM; Kriebel P; Bernstein DC; Biddison WE; Sarngadharan MG; Gallo RC
J Clin Invest; 1985 Oct; 76(4):1699-704. PubMed ID: 2997287
[TBL] [Abstract][Full Text] [Related]
9. Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen.
McDougal JS; Mawle A; Cort SP; Nicholson JK; Cross GD; Scheppler-Campbell JA; Hicks D; Sligh J
J Immunol; 1985 Nov; 135(5):3151-62. PubMed ID: 2995487
[TBL] [Abstract][Full Text] [Related]
10. The Vancouver Lymphadenopathy-AIDS Study: 4. Effects of exposure factors, cofactors and HTLV-III seropositivity on number of helper T cells.
Schechter MT; Boyko WJ; Jeffries E; Willoughby B; Nitz R; Constance P; Weaver M; Wiggs B; O'Shaughnessy M
Can Med Assoc J; 1985 Aug; 133(4):286-92. PubMed ID: 2990652
[TBL] [Abstract][Full Text] [Related]
11. [The acquired immunodeficiency syndrome (AIDS)].
Bogdan C; Solbach W
Fortschr Med; 1985 Sep; 103(35):817-21. PubMed ID: 2414195
[No Abstract] [Full Text] [Related]
12. Clinical and immunological findings in HTLV-III infection.
Krohn KJ; Antonen J; Valle SL; Kazakevicius R; Saxinger C; Gallo RC; Ranki A
Cancer Res; 1985 Sep; 45(9 Suppl):4612s-4615s. PubMed ID: 2990694
[TBL] [Abstract][Full Text] [Related]
13. Human T-cell leukemia virus: its discovery and role in leukemogenesis and immunosuppression.
Shaw GM; Broder S; Essex M; Gallo RC
Adv Intern Med; 1984; 30():1-27. PubMed ID: 6084947
[TBL] [Abstract][Full Text] [Related]
14. HTLV-III AIDS link.
Bennett JA
Am J Nurs; 1985 Oct; 85(10):1086-9. PubMed ID: 2996353
[TBL] [Abstract][Full Text] [Related]
15. Prospects for treatment of human retrovirus-associated diseases.
Bolognesi DP; Fischinger PJ
Cancer Res; 1985 Sep; 45(9 Suppl):4700s-4705s. PubMed ID: 2410116
[TBL] [Abstract][Full Text] [Related]
16. [Diagnosis and therapy of pneumocystis carinii pneumonia in a patient with AIDS].
Schur W; Asamer H
Wien Klin Wochenschr; 1986 Mar; 98(5):137-41. PubMed ID: 3008447
[TBL] [Abstract][Full Text] [Related]
17. Retroviruses associated with leukemia and ablative syndromes in animals and in human beings.
Essex M; McLane MF; Kanki P; Allan J; Kitchen L; Lee TH
Cancer Res; 1985 Sep; 45(9 Suppl):4534s-4538s. PubMed ID: 2990682
[TBL] [Abstract][Full Text] [Related]
18. Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo.
Broder S; Yarchoan R; Collins JM; Lane HC; Markham PD; Klecker RW; Redfield RR; Mitsuya H; Hoth DF; Gelmann E
Lancet; 1985 Sep; 2(8456):627-30. PubMed ID: 2863631
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone.
Sarin PS; Sun D; Thornton A; Müller WE
J Natl Cancer Inst; 1987 Apr; 78(4):663-6. PubMed ID: 2435942
[TBL] [Abstract][Full Text] [Related]
20. Analysis of effector mechanisms against HTLV-I- and HTLV-III/LAV-infected lymphoid cells.
Ruscetti FW; Mikovits JA; Kalyanaraman VS; Overton R; Stevenson H; Stromberg K; Herberman RB; Farrar WL; Ortaldo JR
J Immunol; 1986 May; 136(10):3619-24. PubMed ID: 2422259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
